PGNY
$18.13-0.05 (-0.28%)
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. The company offers fertility benefits solutions, such as differentiated benefits plan design that includes ...
Recent News
Progyny CEO Details Utilization Trends, Forecasting and Progyny Select Fully Insured Rollout at Conference
Progyny (NASDAQ:PGNY) CEO Pete Anevski outlined how the company is thinking about utilization trends, forecasting, and the rollout of its new fully insured product during a fireside chat hosted by KeyBanc healthcare tech analyst Scott Schoenhaus. The discussion followed the company’s fourth-quarter
Reflecting On Health Insurance Providers Stocks’ Q4 Earnings: Progyny (NASDAQ:PGNY)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Progyny (NASDAQ:PGNY) and the best and worst performers in the health insurance providers industry.
Assessing Progyny (PGNY) Valuation After Recent Share Price Weakness
Recent share performance and business snapshot Progyny (PGNY) has drawn attention after a period of weaker share performance, with returns of an 18.8% decline over the past month and a 34.5% decline over the past 3 months. This has prompted closer scrutiny of the underlying business. The company operates as a benefits manager focused on fertility, family building and women’s health in the United States. It generates US$1.29b in revenue and US$58.52m in net income from services that span...
3 Out-of-Favor Stocks with Open Questions
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
Barclays Raises Hims & Hers (HIMS) Target to $29 After Novo Deal Clears Legal Overhang — Canaccord Cuts Progyny (PGNY) on Cautious 2026 Outlook
Two healthcare names are drawing fresh analyst attention this week as Wall Street recalibrates around a landmark GLP-1 truce and a fertility benefits company navigating a murky 2026 outlook. Barclays analyst Glen Santangelo raised his price target on Hims & Hers Health to $29 from $25, keeping an Overweight rating, after the company’s deal with ... Barclays Raises Hims & Hers (HIMS) Target to $29 After Novo Deal Clears Legal Overhang — Canaccord Cuts Progyny (PGNY) on Cautious 2026 Outlook